Anti-inflammatory add-on treatment is beneficial for patients with major depressive disorder (MDD) or depressive symptoms.
All articles by Jennifer Mannheim
The Food and Drug Administration (FDA) has granted Fast Track designation to nalmefene HCl injection (Purdue Pharma) for the emergency treatment of known or suspected opioid overdoses.
Cognitive delays and poor academic performance are negative outcomes associated with excessive screen time.
Trazodone is not associated with a reduced risk for dementia compared with other antidepressants at the prodromal stage of disease.
Since 1990, the age-standardized mortality rate for suicide has decreased worldwide.
Few adolescents meet sleep, physical activity, and screen-time guidelines concurrently.
The FDA has issued a Complete Response Letter to Alkermes regarding the New Drug Application for ALKS 5461, an investigational adjunctive treatment for major depressive disorder.
Physicians who receive direct pharmaceutical payments for opioid prescribing prescribe more opioids, especially hydrocodone and oxycodone.
Improving clinic capacity to respond to patients’ social needs may reduce primary care physician burnout.
More than two-thirds of stroke survivors aged 50 years or older report being in complete mental health.
Latest News Your top articles for Wednesday
Haymarket Medical NetworkTop Picks